{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.74","upperLimit":"0.91","value":"0.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"Probability of no relapse, secondary malignancy, or death whichever occurs first","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.\n\nDactinomycin: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTherapeutic Conventional Surgery: Undergo surgical resection\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Arm 1 (Bilateral Wilms Tumors)"}],"paramType":"MEAN","populationDescription":"All eligible BWT patients. 6 patients were excluded due to ineligibility and 6 patients were excluded due to protocol violation.","reportingStatus":"POSTED","timeFrame":"4 years from study enrollment","title":"Event-Free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Probability"}